Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of 627 in Healthy Adult Subjects
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-627 in healthy adult subjects after single subcutaneous injection.
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SSGJ-627 in Healthy Adult Subjects
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
108
Start Date
2025-07-20
Completion Date
2026-09-18
Last Updated
2025-07-15
Healthy Volunteers
Yes
Conditions
Interventions
627
subcutaneous injection
Placebo
Single subcutaneous injection